Psoriasis : Targets and Therapy
Overview
Psoriasis : Targets and Therapy is a scientific journal, published by Dove Medical Press since 2011 in English. The journal's country of origin is New Zealand.
Details
Details
Abbr.
Psoriasis (Auckl)
Publisher
Dove Medical Press
Start
2011
End
Continuing
e-ISSN
2230-326X
Country
New Zealand
Language
English
Recent Articles
1.
Krefting F, Scheib C, Benson S, Holsken S, Placke J, Wedemeyer H, et al.
Psoriasis (Auckl)
. 2025 Mar;
15:29-44.
PMID: 40046951
Purpose: Modern systemic therapies offer a high probability of significant improvement for psoriasis. However, elevated liver function tests (LFTs) may cause physicians to be reluctant to initiate systemic treatment. Especially...
2.
Christov S, Ohm F, Augustin M, Wagner J
Psoriasis (Auckl)
. 2025 Jan;
15:23-28.
PMID: 39866910
Linear psoriasis (LP) represents a rare variant of psoriasis. The clinical presentation includes erythematous plaques distributed along the Blaschko lines, reflecting the presence of embryological mosaicism. The clinical and histopathological...
3.
Holsken S, Krefting F, Muhlhaus S, Bese D, Schedlowski M, Sondermann W
Psoriasis (Auckl)
. 2025 Jan;
15():9-22.
PMID: 39810930
Purpose: Patients' treatment expectations significantly influence the effectiveness of medical and pharmacological treatments. This clinical proof-of-concept study aimed to enhance treatment outcomes by targeting positive treatment expectations of psoriasis patients...
4.
Damsin T, Absil G, Libon F, Tassoudji N, Nikkels A
Psoriasis (Auckl)
. 2025 Jan;
15():1-8.
PMID: 39781106
Background: Biological therapies, including TNF-alpha, IL12/23, IL17 and IL23 antagonists, adequately control a very high number of patients with moderate-to-severe psoriasis with an excellent long-term safety profile. However, on occasion,...
5.
Wei L, Zhang B, Tu Y, Liu A
Psoriasis (Auckl)
. 2025 Jan;
14:195-206.
PMID: 39759475
Psoriasis is a chronic inflammatory disease with a complex pathogenesis. Hyperplasia of glycolytic-dependent epidermal keratinocytes (KCs) is a new hallmark of psoriasis pathogenesis. Meanwhile, immune cells undergo metabolic reprogramming similar...
6.
Mao R, Zhang T, Yang Z, Li J
Psoriasis (Auckl)
. 2024 Dec;
14:179-193.
PMID: 39669686
Background: Current pharmacological treatments for psoriasis are generally non-specific and have significant limitations, particularly in the realm of targeted biologic therapies. There is an urgent need to identify and develop...
7.
Wang L, Zou S, Zhu Y
Psoriasis (Auckl)
. 2024 Dec;
14:175-178.
PMID: 39635305
Acrodermatitis enteropathica (AE) can be caused by inherited or acquired zinc deficiency, among which site-specific skin lesions or even psoriasiform skin manifestations are present. Few cases exist in the literature...
8.
Patel V, Park S, Zhong Y, Sima A, Zhuo J, Roberts-Toler C, et al.
Psoriasis (Auckl)
. 2024 Dec;
14:167-174.
PMID: 39624651
Purpose: This real-world study investigated the impact of patient-reported disease burden and health-related quality of life (HRQoL) on switching from systemic nonbiologic to biologic therapy in patients with plaque psoriasis....
9.
Wu C, He C, Wang H, Wang W, Jin H
Psoriasis (Auckl)
. 2024 Dec;
14:153-166.
PMID: 39619374
Purpose: This prospective observational study investigated whether interleukin (IL)-17A inhibitors could reduce serum uric acid (SUA) levels in psoriatic patients with hyperuricemia. It also explored the risk factors for hyperuricemia...
10.
Haran K, Johnson C, Smith P, Venable Z, Kranyak A, Bhutani T, et al.
Psoriasis (Auckl)
. 2024 Nov;
14:143-152.
PMID: 39564576
Psoriasis is an immune-mediated skin disease known to be associated with a higher risk of cardiometabolic comorbidities such as hypertension, myocardial infarction, and stroke. GLP-1 receptor agonists (GLP-1RAs) are medications...